Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? by Twelves, C J & Cassidy, J
Review
Which endpoints should we use in evaluating the use of novel
ﬂuoropyrimidine regimens in colorectal cancer?
CJ Twelves*
,1 and J Cassidy
2
1Cancer Research UK Department of Medical Oncology, Alexander Stone Building, Garscube Estate, Switchback Road, Bearsden, Glasgow G61 1BD, Scotland,
UK;
2Department of Medicine and Therapeutics, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK
Although signiﬁcant advances have been made in the treatment of advanced/metastatic colorectal cancer, 5-ﬂuorouracil (5-FU)
still forms the basis of chemotherapy. Recently, new 5-FU schedules and novel ﬂuoropyrimidines have been developed, but
there are no trials directly comparing these regimens. The current review describes the mechanisms of action, pre-clinical and
phase I/II studies of two oral ﬂuoropyrimidine therapies, capecitabine and uracil with tegafur plus leucovorin. It also compares
the phase III studies of these agents with those of the two most popular infusional 5-FU-based regimens: de Gramont and
German AIO (The Association of Medical Oncology (AIO) of the German Cancer Society). Both oral and infusional regimens
demonstrated similar survival to the Mayo Clinic regimen, a standard treatment for colorectal cancer. Therefore, other
endpoints must be examined to decide optimum therapy, including response rates, time to disease progression, tolerability
and patients’ convenience. All four new therapies demonstrated superior safety proﬁles compared with the Mayo Clinic
regimen. However the uracil with tegafur plus leucovorin regimen was associated with severe diarrhoea and capecitabine with
hand–foot syndrome. Patients will not sacriﬁce efﬁcacy for the convenience of oral therapy alone, therefore the fact that
capecitabine achieved superior response rates and equivalent time to disease progression compared with the Mayo Clinic
regimen, while uracil with tegafur plus leucovorin produced lower response rates and signiﬁcantly inferior time to disease
progression, is highly relevant in choosing treatment.
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Colorectal cancer is the third most common cancer in men and
women, accounting for 783000 new cases and 437000 deaths
worldwide in 1990 (Pisani et al, 1999; Parkin et al, 1999). About
40–50% of patients develop metastatic disease. The aims of any
therapy in patients with advanced colorectal cancer are to control
symptoms, maintain or improve quality of life and ultimately to
prolong survival. Recent meta-analyses conﬁrmed that chemother-
apy prolongs time to disease progression (TTP) and survival in
patients with advanced or metastatic colorectal cancer, compared
with best supportive care or observation/no chemotherapy (Color-
ectal Cancer Collaborative Group, 2000; Jonker et al, 2000).
The ﬂuoropyrimidine, 5-ﬂuorouracil (5-FU), has formed the
basis of chemotherapy for colorectal cancer for over 40 years.
Numerous 5-FU-based schedules are used, and extensive efforts
have been made to increase their activity, including biomodulation,
modiﬁcation of the dose or schedule and the use of analogues/
prodrugs.
The most successful biomodulation of 5-FU has been with
leucovorin (LV), a derivative of tetrahydrofolic acid, the reduced
form of folic acid. The rationale is that in the presence of reduced
folate, ﬂuorodeoxyuridine monophosphate (a metabolite of 5-FU),
covalently interacts with thymidylate synthase, which is the source
for de novo synthesis of thymidine nucleotides, ultimately disrupt-
ing DNA synthesis. In a meta-analysis, the addition of LV to 5-FU
signiﬁcantly improved response rates in patients with advanced
colorectal cancer (23% vs 11%; P510
77), although there was no
difference in overall survival (Advanced Colorectal Cancer Meta-
Analysis Project, 1992).
With regards to optimising the 5-FU schedule, continuous or
protracted infusion is more effective than bolus administration in
terms of response rates and TTP. In a phase III trial comparing
continuous intravenous 5-FU infusion (750 mg m
72 day
71, daily
for 7 days, every 21 days) with bolus administration
(500 mg m
72 day
71, daily for 5 days, every 28 days) in patients
with metastatic colorectal cancer, the response rate was signiﬁcantly
higher in the infusion group than the bolus group (26 vs 13%;
P50.04), (Rougier et al, 1997). Again, no difference in overall
survival was observed. The superiority of continuous infusion
was conﬁrmed by a meta-analysis in which it achieved a signiﬁ-
cantly higher response rate than bolus 5-FU (22 vs 14%;
P=0.0002) (Meta-analysis Group In Cancer, 1998). However, the
increase in overall survival (12.1 months vs 11.3 months; P=0.04)
was small and probably not clinically meaningful.
Raltitrexed is a direct, speciﬁc inhibitor of thymidylate synthase.
It is structurally distinct from the ﬂuoropyrimidines and has the
advantage of being administered as an intravenous bolus every 3
weeks. Objective response rates with raltitrexed are similar to those
with 5-FU plus LV (Cunningham, 1998) but recent trials have
demonstrated inferior efﬁcacy (TTP/survival) or raised safety
concerns. Most recently, other agents with novel molecular targets
have shown clear evidence of activity in colorectal cancer. Irinote-
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when added to 5-FU plus LV (Douillard et al, 2000; Saltz et al,
2000) and in second-line therapy as a single agent when compared
with best supportive care or infusional 5-FU (Cunningham et al,
1998; Rougier et al, 1998). Of note, this improvement in survival
required the use of a new family of drugs directed to a novel target,
whereas survival differences have been difﬁcult to identify in trials
of ﬂuoropyrimidines. Similarly, oxaliplatin substantially increases
response rates when added to infusional 5-FU plus LV, although
improved overall survival has not yet been demonstrated (de
Gramont et al, 2000; Giacchetti et al, 2000).
The Mayo Clinic regimen is a commonly used 5-FU treatment,
which has conﬁrmed efﬁcacy (Poon et al, 1991). It comprises bolus
LV, 20 mg m
72 followed by bolus 5-FU, 425 mg m
72, both admi-
nistered daily for 5 days, every 4 weeks. The Mayo Clinic regimen
in various forms has been used as the control arm in numerous
colorectal cancer clinical trials (de Gramont et al, 1997; Aranda
et al, 1998; Cunningham, 1998; Carmichael et al, 1999; Pazdur et
al, 1999; Young et al, 1999; Buechele et al, 2000; Maughan et al,
2000; Saltz et al, 2000, 2002; Schmoll et al, 2000; Wang et al,
2000; Hoff et al, 2001; Van Cutsem et al, 2001; Twelves, 2002).
This review describes four phase III studies in detail, concentrat-
ing on the signiﬁcance of different endpoints in colorectal cancer.
Two of these studies investigated the oral therapies, capecitabine
(Xeloda
1), and a combination of UFT (uracil and ftorafur, also
known as tegafur (Orzel
TM, Uftoral
TM) plus LV. The mechanisms
of action, and pre-clinical and phase I/II studies of capecitabine
and UFT plus LV are also described. The other studies investigated
two of the most popular infusional 5-FU-based regimens, the de
Gramont and the German AIO regimens.
Investigation of endpoints across these different trials is impor-
tant because these new oral ﬂuoropyrimidines and infusional
regimens have not been directly compared in clinical trials, and
such trials are unlikely in the future. Although it is not necessarily
the most widely used regimen, the Mayo Clinic is useful as a
common comparator across clinical trials.
ORAL REGIMENS
Capecitabine
Capecitabine has recently been approved in Europe and the USA
for use in advanced colorectal cancer. It is a novel ﬂuoropyrimi-
dine carbamate, rationally designed to be taken orally and
through a three step process generate 5-FU preferentially in
tumour tissue. Thus, capecitabine mimics protracted 5-FU infusion
but with a more convenient mode of administration. It also poten-
tially reduces systemic exposure to 5-FU, thereby improving the
therapeutic index (Di Costanzo et al, 2000). Pre-clinical work
showed that capecitabine had superior anti-tumour activity in
various human cancer xenograft models compared with UFT or
5-FU (Ishikawa et al, 1998b), as well as anti-tumour activity in
5-FU-sensitive and 5-FU-resistant tumours (Cao et al, 1997).
Capecitabine is not itself cytotoxic but is ﬁrst converted to 5'-
deoxy-5-ﬂuorocytidine (5'-DFCR) by carboxylesterase, located
primarily in the liver. Next, 5'-DFCR is converted to 5'-deoxy-5-
ﬂuorouridine (5'-DFUR) by cytidine deaminase, present mainly
in the liver and tumour tissue. Finally, 5'-DFUR is converted to
5-FU by thymidine phosphorylase, which has signiﬁcantly higher
activity in tumour than normal tissues (Ishikawa et al, 1998a).
Preferential activation of capecitabine to 5-FU in patients was
demonstrated in a recent study, in which exposure to 5-FU in
primary colorectal tumours was on average 3.2 times higher than
in adjacent healthy tissue (P=0.002), and 21.4 times higher than
in plasma (Schu ¨ller et al, 2000).
In a phase I study using an intermittent schedule (2 weeks treat-
ment followed by a 1-week rest period), the dose-limiting toxicities
(DLTs) were diarrhoea with hypotension, abdominal pain and
leucopenia (Mackean et al, 1998). Other phase I studies evaluated
a continuous schedule (Budman et al, 1998) and the combination
of capecitabine with oral LV (Cassidy et al, 1998). A randomised
phase II study in colorectal cancer patients comparing these three
schedules reported response rates of 24, 21 and 23%, respectively;
all three schedules were generally well tolerated (Van Cutsem et al,
2000). Based on considerations of toxicity, dose-intensity, response
rate and TTP, the intermittent capecitabine monotherapy regimen
(2-weeks treatment, 1-week rest) was selected for subsequent phase
III studies, with a recommended starting dose of 1250 mg m
72
twice daily.
UFT plus LV
UFT is an orally administered combination of tegafur and uracil
in a ﬁxed 1:4 molar ratio that has been available in Japan since
1984. Tegafur is a 5-FU prodrug that is converted to 5-FU by
hepatic microsomal cytochrome P450 enzymes, or by ubiquitous
cytosolic enzymes. The rationale for the addition of uracil is that
it competes with 5-FU as a substrate for dihydropyrimidine dehy-
drogenase, the rate-limiting enzyme responsible for 5-FU
catabolism, thus preventing the typical rapid breakdown of 5-
FU. In high doses, tegafur is associated with neurological adverse
effects, including depression, headache and dizziness, in which the
metabolite alpha–ﬂuoro–beta–alanine appears to play a crucial
role. Uracil greatly reduces the dose of tegafur used, thus reducing
the concentration of this metabolite. In animals, the co-adminis-
tration of uracil and tegafur reduced tegafur neurotoxicity
(Yamamoto et al, 1984). The rationale for the addition of LV
to UFT follows that of adding LV to 5-FU. Evidence for the bene-
ﬁt of adding LV to UFT comes from a study in which LV
signiﬁcantly enhanced the growth-suppressive ability of UFT
against human colon and mammary tumour xenografts (Okabe
et al, 1997).
The MTD of UFT plus LV was determined in several phase I
studies using UFT administered in divided doses for 14 days every
4 weeks or for 28 days every 5–6 weeks; LV doses varied 10-fold
(Hoff, 2000). The DLTs consisted of diarrhoea, vomiting, fatigue,
stomatitis, abdominal pain, leucopenia and abnormal liver function
tests. In phase II trials, UFT plus LV achieved response rates
between 0 and 42%. However, these trials suggest a narrow
dose–toxicity relationship, given that lowering the UFT dose from
350 to 300 mg m
72 day
71 markedly reduced the incidence of
grade 3 diarrhoea from 71 to 11% (Hoff, 2000; Pazdur et al,
1994). Based on these results, UFT 300 mg day
71, with LV 75–
90 mg day
71, was given for 28 days and repeated every 5 weeks
in phase III colorectal cancer studies.
ORAL AND INFUSIONAL REGIMENS VS MAYO CLINIC
REGIMEN – PHASE III DATA
Table 1 shows the four phase III trials of ﬁrst-line treatment for
colorectal cancer to be discussed, using the Mayo Clinic regimen
as the comparator. The novel treatments investigated were oral
capecitabine (Twelves, 2002), UFT plus LV (Pazdur et al, 1999),
and two infusional 5-FU-based regimens (de Gramont et al,
1997; Schmoll et al, 2000). The capecitabine data comprises pooled
results from two phase III trials, with identical protocols and
conduct. One study was conducted in Europe, Australia and Asia
(Van Cutsem et al, 2001), and the other in the USA, Brazil and
Mexico (Hoff et al, 2001). The UFT plus LV trial was performed
in Europe, the USA and Canada, while the de Gramont regimen
trial was performed in France. The EORTC/AIO study was a 3-
arm trial, with infusional 5-FU given with or without LV, in which
the Mayo Clinic regimen was administered every 4 weeks for two
cycles and then every 5 weeks. Additional information on these
trials is cited elsewhere (Benner, 1999; Cassidy, 2000; Cunningham
and James, 2001).
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ences are evident. These include inter-assessment intervals, which
is pertinent as longer periods can result in cruder estimation of some
endpoints such as TTP (Cassidy, 2000). Furthermore, the analysis
population was substantially smaller than the all randomised popu-
lation in the de Gramont trial, and only patients with measurable
disease were included in the response rate analysis in the EORTC/
AIO study. The trials with the oral compounds were for registration
purposes, so use of the all randomised population for efﬁcacy para-
meters was mandatory and safety was monitored intensively.
Efﬁcacy
None of the four trials achieved a signiﬁcant survival advantage
over the Mayo Clinic regimen (Table 2). Only the capecitabine
studies used response rate as a primary endpoint, these trials being
designed and statistically powered to demonstrate equivalent rather
than superior survival. Capecitabine achieved signiﬁcantly higher
response rates than the Mayo Clinic regimen (P50.0002),
conﬁrmed by independent review committee (IRC) assessment
(Table 3). Moreover, capecitabine showed a consistent and signiﬁ-
cantly higher (P50.05) response rate in all subpopulations
analysed (prior adjuvant therapy, predominant site of metastases,
single/multiple sites and Karnofsky Performance Status) (Twelves,
2002). Capecitabine produced an equivalent median TTP to the
Mayo Clinic regimen (Table 3).
In contrast to the results obtained with capecitabine, UFT plus
LV produced a lower response rate than the Mayo regimen,
although this difference was not statistically signiﬁcant. TTP was,
however, signiﬁcantly inferior with UFT plus LV compared to
the Mayo Clinic regimen and recalculating published data (Benner,
1999) using the study arm as the denominator in line with the
capecitabine study, the hazard ratio was 1.22 (P=0.01). This
equates to a 22% increased risk of disease progression, with UFT
plus LV compared with the Mayo Clinic regimen (Figure 1). A
second phase III trial involving 380 patients, compared UFT/LV
with a non-standard Mayo Clinic regimen (of 5-FU/LV given every
5 weeks, rather than 4 weekly). In this trial UFT/LV produced no
signiﬁcant difference in survival, response rates or median TTP
(Carmichael et al, 1999). However, as highlighted by the US Food
and Drug Administration (FDA), the control arm in this study had
a planned 25% lower dose intensity than the standard Mayo Clinic
regimen. Although the difference in delivered dose intensity was
less, this may explain the differences in results between the two
UFT plus LV phase III studies (Benner, 1999). Moreover, there
are insufﬁcient data on the efﬁcacy of this non-standard Mayo
Clinic regimen for it to be a valid comparator.
The de Gramont regimen achieved a statistically signiﬁcant
improvement in response rates. However, the response rate analysis
was based on only three quarters of the randomised population. A
large difference was observed in response rates between the
EORTC/AIO (20.5%) and Mayo Clinic regimens (11.5%), but this
did not reach statistical signiﬁcance, most likely because relatively
few patients had measurable disease. Both the de Gramont and
EORTC/AIO plus LV regimens produced modest, but statistically
signiﬁcant, improvements in median TTP, although estimates in
the de Gramont study are cruder due to the longer inter-assess-
ment intervals.
In summary, the infusional regimens produced signiﬁcant
improvements in TTP, whereas UFT plus LV produced a signiﬁ-
cantly inferior TTP; oral capecitabine and the de Gramont
regimen resulted in signiﬁcant improvements in response rates.
Safety proﬁles
Since therapy in this setting is generally given with palliative intent,
it is important to consider toxicity carefully. In terms of overall
incidence, capecitabine caused signiﬁcantly less diarrhoea, nausea,
stomatitis and alopecia compared with the Mayo Clinic regimen
(Hoff et al, 2001; Van Cutsem et al, 2001) and UFT plus LV signif-
icantly less diarrhoea, neutropenia, nausea/vomiting and stomatitis/
mucositis (Pazdur et al, 1999).
Looking at grade 3 or 4 toxicities, all four regimens were asso-
ciated with less severe neutropenia/leucopenia (all differences
statistically signiﬁcant, apart from EORTC/AIO) and a lower inci-
dence of severe stomatitis/mucositis than the Mayo Clinic regimen.
With the exception of capecitabine, there was a trend towards a
higher incidence of grade 3 or 4 nausea and vomiting with the
new regimens in all trials. Grade 3/4 diarrhoea was signiﬁcantly less
frequent with the de Gramont than the Mayo Clinic regimen, while
the EORTC/AIO plus LV regimen was associated with more diar-
rhoea than the EORTC/AIO regimen without LV and the Mayo
Clinic regimen. No signiﬁcant difference in the incidence of grade
3 or 4 diarrhoea was observed with capecitabine compared with the
Table 1 Details of phase III oral and infusional 5-FU-based colorectal cancer studies using the Mayo Clinic regimen as a comparator
Regimen Treatment schedule Analysis populations (n)
Inter-assessment interval
(weeks) Primary endpoint
Oral
Capecitabine 1250 mg m
72, twice daily for 14 days, every 3 weeks Randomised=1207
Efﬁcacy analysis:
Capecitabine=603
Mayo Clinic=604
Safety analysis:
Capecitabine=596
Mayo Clinic=593
6 Response rate
(Secondary endpoint=survival
and TTP)
UFT plus LV UFT, 300 mg m
72, and LV, 75 or 90 mg, for 28 days
every 5 weeks
Randomised=816 8–10 Survival
Infusional
de Gramont IV LV, 200 mg m
72, as a 2-hour infusion followed by
IV bolus 5-FU, 400 mg m
72, and 22-hour infusion
5-FU, 600 mg m
72, for 2 consecutive days every
2 weeks
Randomised=448
Survival analysis=443
Response rate analysis=348
Safety analysis=413
12 Survival
EORTC/AIO Randomised=497 4 Survival
(7LV) IV 5-FU, 2600 mg m
72, 24-hour infusion weekly,
weeks 1–6, followed by 2 weeks’ rest
Safety analysis=421
Response rate analysis=303
(+LV) Same regimen+LV, 500 mg m
72, 2-hour infusion
LV=leucovorin; IV=intravenous; TTP=time to disease progression; 5-FU=5-ﬂuorouracil.
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Fisher’s Exact test (Benner, 1999; Pazdur et al, 1999) showed a
trend for increased incidence of grade 3 or 4 diarrhoea with
UFT plus LV (P=0.057), based on a safety population of 406
patients for UFT plus LV and 396 for the Mayo Clinic regimen
(Cunningham and James, 2001). This high incidence of grade 3
or 4 diarrhoea (21%) has also been observed in a phase III adju-
vant trial (26%) (Smith et al, 1999).
Hand–foot syndrome, a cutaneous condition affecting palms and
soles, is one of the more common adverse effects of capecitabine,
but is usually mild or moderate in intensity. In the capecitabine trial,
only two out of the 596 patients included in the safety analysis were
hospitalised because of this adverse effect (one patient required an
8-h stay and one needed overnight observation). Hand–foot
syndrome was effectively managed by use of emollients, treatment
interruption or, if necessary, dose reduction which prevented recur-
rence of grade 2/3 hand–foot syndrome in all but 45 out of 171
patients (Cassidy and Twelves, 2000). Efﬁcacy was maintained in
those patients who required dose modiﬁcation, as indicated by a
Cox regression analysis of TTP in patients with and without dose
reduction, in which the hazard ratio was 0.97 (P=0.78).
ORAL AND INFUSIONAL REGIMENS – TREATMENT
CHOICE
It is clear that neither the oral nor infusional ﬂuoropyrimidine
regimens discussed offer any signiﬁcant beneﬁt in overall survival
compared with the Mayo Clinic regimen. Likewise, although
continuous infusion of 5-FU achieves higher response rates than
the Mayo Clinic regimen, this does not impact on survival (Aranda
et al, 1998; Rougier et al, 1998). Therefore, other factors must be
taken into consideration when choosing appropriate chemotherapy,
including TTP, response rates and tolerability.
Infusional regimens are time-consuming, inconvenient and
uncomfortable for the patient, and often require regular hospital
visits. They are also frequently associated with venous access-related
complications, such as infections, sepsis, thrombosis and blockage.
In subsets of patients with in-dwelling central venous catheters,
more than 60% develop upper extremity deep vein thrombosis
(Prandoni and Bernardi, 1999) and infection rates of 10–30% have
been reported (Clark and Rafﬁn, 1990). The administration schedule
of raltitrexed as an intravenous infusion over 15 min, repeated every
3 weeks, offers increased convenience for the patient. Raltitrexed was
Table 2 Median survival times for phase III oral and infusional 5-FU-based colorectal cancer studies and log-rank comparison of the entire
survival curves
Survival time (months)
Regimen Study treatment Mayo Clinic regimen P-value (log-rank test) Hazard ratio (95% CI)
Oral
Capecitabine (Twelves, 2002) 12.9 12.8 0.48 0.96 (0.85–1.08)*
UFT plus LV (Benner, 1999) 12.4 13.4 0.65 1.07 (0.92–1.25){
Infusional
de Gramont (de Gramont et al, 1997) 14.2 13.0 0.067 Not available
EORTC/AIO (Schmoll et al, 2000)
(7LV) 12.5 12.0 Not available Not available
(+LV) 13.2 12.0 Not available Not available
*Risk of death is reduced by 4% compared with the Mayo Clinic regimen. {As calculated using the study arm as the denominator. LV=leucovorin.
Table 3 Median TTP, log-rank comparison of the TTP curves and overall response rate for phase III oral and infusional 5-FU-based colorectal cancer
studies
Median TTP (months) Overall response rate (%)
Regimen
Study
treatment
Mayo Clinic
regimen
P-value
(log-rank test)
Hazard ratio
(95% CI)
Study
treatment
Mayo Clinic
regimen
P-value
(Chi-square test)
Oral
Capecitabine (Twelves, 2002) 4.6 4.7 0.95 1.00 (0.89–1.12) 25.7 16.7 50.0002
UFT plus LV (Benner, 1999) 3.5 3.8 0.01 1.22 (1.05–1.41){ 11.7 14.5 0.23
Infusional
de Gramont (de Gramont et al, 1997) 6.3 5.0 0.001 Not available 32.6 14.5 0.004
EORTC/AIO (Schmoll et al, 2000)
(7LV) 4.4 4.0 0.82 0.97 (0.75–1.27)* 9.3 11.5 NS
(+LV) 6.4 4.0 0.02 0.76 (0.58–1)* 20.5 11.5 NS
*98% CI reported. {As calculated using the study arm as the denominator. LV=leucovorin; NS=non-signiﬁcant.
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Figure 1 Time to disease progression Kaplan–Meier curve for the UFT
plus LV vs Mayo Clinic regimen phase III trial (Benner, 1999).
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trials the Mayo regimen was the comparator, so these studies can be
placed alongside those discussed above (Cunningham, 1998). In
both trials the objective response rates were very similar to those
with the Mayo Clinic regimen. In one trial, survival also was iden-
tical. However, in the other trial, median survival was signiﬁcantly
worse with raltitrexed than with 5-FU plus LV (9.7 and 12.7
months, respectively; P=0.01). There was also a marked difference
in duration of chemotherapy, with patients remaining on treatment
for substantially longer in the 5-FU plus LV arm. Although in some
studies raltitrexed was better tolerated than bolus 5-FU plus LV, in
another it was associated with an excess of treatment-related deaths
in comparison with infusional 5-FU (Maughan et al, 2000). The
development of raltitrexed in the adjuvant setting was abandoned
because of these concerns.
Oral therapy overcomes the delivery problems associated with
infusional regimens and a recent questionnaire study showed that
patients have a strong preference for oral rather than intravenous
treatment (Liu et al, 1997). Of 103 assessable patients with incur-
able cancer, 89% expressed a preference for oral rather than
intravenous chemotherapy. The main reasons for preferring oral
treatment were convenience (57%), problems with intravenous
lines (55%) and control over the environment in which they
received chemotherapy (33%). However, more than two thirds of
patients did not want to sacriﬁce response rate (70%) or response
duration (74%) for the convenience of oral treatment. Patient
preference for oral administration was conﬁrmed by a prospective
clinical study, in which 84% of patients preferred oral UFT plus LV
to intravenous 5-FU plus LV (Borner et al, 2002).
Given that patients are reluctant to sacriﬁce efﬁcacy for conveni-
ence, the fact that capecitabine produced superior response rates
and equivalent TTP compared with the Mayo Clinic regimen, while
UFT plus LV produced lower response rates and inferior TTP, is
relevant when considering treatment options. Patients’ reluctance
to sacriﬁce efﬁcacy is also relevant when considering the use of ralti-
trexed. Although raltitrexed may have a place in the treatment of
some patients who cannot tolerate 5-FU (Taylor, 2000), the results
of clinical trials question its efﬁcacy compared to commonly used 5-
FU/LV regimens. Unlike intravenous regimens, oral agents are not
associated with risk of local toxicity related to their administration
or placement of an in-dwelling central venous catheter. For the
patient, oral chemotherapy substantially reduces the amount of time
spent at the hospital for treatment and is clearly more convenient
(Twelves et al, 2001). However, another factor to be considered
when comparing oral therapies is the timing of treatment. UFT plus
LV should be given every 8 h, at least 1 h before or after meals,
creating practical difﬁculties that may impact upon quality of life.
By contrast, no clinically relevant differences in the pharmacoki-
netics of capecitabine and its metabolites were observed in
patients taking capecitabine under fasting conditions or after a stan-
dard meal (Reigner et al, 1998). It is recommended that capecitabine
be administered twice daily within 30 min after breakfast and an
evening meal with water to mimic the clinical trials, but this should
cause little if any disruption to patients’ lifestyles.
The considerable advantages associated with oral agents mean
that they will soon ﬁnd a place in routine practice (Young and
Rea, 2000). With capecitabine these advantages also extended to
substantial savings in medical resource use (Twelves et al, 2001).
SUMMARY
The ultimate aim in the treatment of any patient with colorectal
cancer is to increase their survival, but neither the oral nor infu-
sional ﬂuoropyrimidine therapies discussed achieved this goal
compared with the standard Mayo Clinic regimen. Furthermore,
patients and physicians face practical problems when choosing
between the new ﬂuoropyrimidines, as many clinicians use one
of the other infusional treatments rather than the Mayo Clinic regi-
men. In the absence of direct, comparative trials between these
regimens, clinicians have no choice but to make the best indirect
comparisons possible, using the Mayo Clinic regimen as the
common link.
Both oral capecitabine and the infusional de Gramont regimens
signiﬁcantly improved response rates compared with the Mayo
Clinic regimen. Moreover, the de Gramont and EORTC/AIO plus
LV infusional regimens signiﬁcantly, but modestly, improved
TTP. In contrast, UFT plus LV resulted in a 22% increased risk
of disease progression. All four therapies demonstrated superior
safety proﬁles compared with the Mayo Clinic regimen although
differences in the type and severity of adverse effects were observed.
In terms of patients’ convenience, oral therapy is preferable to infu-
sional regimens, but patients will not sacriﬁce efﬁcacy for
convenience. This would favour the choice of capecitabine over
UFT plus LV.
The treatment of colorectal cancer is evolving rapidly, with one
focus the choice between combination and sequential chemother-
apy. Efﬁcacy can be enhanced by combining 5-FU/LV with either
irinotecan (Cunningham et al, 1998; Rougier et al, 1998; Douillard
et al, 2000; Saltz et al, 2000) or oxaliplatin (de Gramont et al, 2000;
Giacchetti et al, 2000). A logical step forward would be to use an
oral ﬂuoropyrimidine, in combination with oxaliplatin or irinote-
can, or with radiotherapy in patients with rectal cancer. Already,
several phase I/II studies have been undertaken combining UFT
or capecitabine with oxaliplatin or irinotecan. In the setting of
ﬁrst-line combination therapy, where increased survival has already
been shown, the evidence that capecitabine is the more active of
the oral ﬂuoropyrimidines suggests it is an especially attractive
partner for oxaliplatin and irinotecan. The deﬁnitive answer as to
which is the optimal combination will depend on large-scale,
comprehensive studies, the results of which are eagerly awaited.
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